Whether in AD (via TNF‐α blockade reducing synaptotoxicity), autoimmune diseases (via IL‐6 or IFN‐α antagonism mitigating neuroinflammation), or cancer‐associated syndromes (via IL‐1/IL‐6 neutralization alleviating pain and cachexia), cytokine modulation demonstrates a dual therapeutic mechanism: restoring immune balance and alleviating associated neurological complications. The gene discussed is IFNA1; the disease is autoimmune disease.